Q2 2024 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2024-08-12 · accession 0000950123-24-007830
$910.8M
Reported value
25
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $204.6M | 22.5% | 2,697,267 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $201.2M | 22.1% | 10,473,913 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $80.9M | 8.89% | 1,795,735 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $78.0M | 8.56% | 3,013,423 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $62.1M | 6.82% | 3,303,381 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $58.7M | 6.44% | 14,565,457 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $41.4M | 4.55% | 8,449,208 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $25.3M | 2.77% | 3,368,370 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $24.8M | 2.72% | 2,892,663 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $22.9M | 2.51% | 4,034,582 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $17.4M | 1.91% | 8,663,673 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $14.2M | 1.56% | 2,749,808 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $13.8M | 1.51% | 5,410,361 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $12.3M | 1.35% | 1,649,964 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $9.8M | 1.08% | 16,915,784 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $9.6M | 1.05% | 1,030,703 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $8.2M | 0.90% | 2,485,638 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $5.6M | 0.61% | 8,434,560 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $5.1M | 0.56% | 1,111,910 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $4.7M | 0.51% | 2,000,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $3.6M | 0.39% | 3,785,450 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $2.7M | 0.29% | 2,267,680 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $2.0M | 0.22% | 1,799,595 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $1.1M | 0.12% | 1,000,000 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $872,000 | 0.10% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.